These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30001845)

  • 1. FDG-PET/CT for Assessing the Response to Neoadjuvant Chemotherapy in Bladder Cancer Patients.
    Soubra A; Gencturk M; Froelich J; Balaji P; Gupta S; Jha G; Konety BR
    Clin Genitourin Cancer; 2018 Oct; 16(5):360-364. PubMed ID: 30001845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.
    van de Putte EEF; Vegt E; Mertens LS; Bruining A; Hendricksen K; van der Heijden MS; Horenblas S; van Rhijn BWG
    Int Urol Nephrol; 2017 Sep; 49(9):1585-1591. PubMed ID: 28674853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy.
    Fitoussi O; Roche JB; Riviere J; Wallerand H; Poulain JE; Gordien P; Galland S; Henriques B; Dupin C; Vincent M; Kuratle T; Saffarini M; Ramos-Pascual S
    Urol Int; 2023; 107(3):239-245. PubMed ID: 36657430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Kollberg P; Almquist H; Bläckberg M; Cwikiel M; Gudjonsson S; Lyttkens K; Patschan O; Liedberg F
    Scand J Urol; 2017 Aug; 51(4):308-313. PubMed ID: 28532260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot Study of [
    Eulitt PJ; Altun E; Sheikh A; Wong TZ; Woods ME; Rose TL; Wallen EM; Pruthi RS; Smith AB; Nielsen ME; Whang YE; Kim WY; Godley PA; Basch EM; David GU; Ramirez J; Deal AM; Rathmell WK; Chen RC; Bjurlin MA; Lin W; Lee JK; Milowsky MI
    Clin Genitourin Cancer; 2020 Oct; 18(5):378-386.e1. PubMed ID: 32147364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and
    Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J
    Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete metabolic response with [
    Abrahamsson J; Kollberg P; Almquist H; Bläckberg M; Brändstedt J; Lyttkens K; Simoulis A; Sjödahl G; Sörenby A; Trägårdh E; Liedberg F
    BJU Int; 2022 Feb; 129(2):174-181. PubMed ID: 33626220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.
    Goodfellow H; Viney Z; Hughes P; Rankin S; Rottenberg G; Hughes S; Evison F; Dasgupta P; O'Brien T; Khan MS
    BJU Int; 2014 Sep; 114(3):389-95. PubMed ID: 24341486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study.
    Richters A; van Ginkel N; Meijer RP; Wondergem M; Schoots I; Vis AN; Kiemeney LALM; van Rhijn BWG; Witjes JA; Aben KKH; Mertens LS
    BJU Int; 2023 Oct; 132(4):420-427. PubMed ID: 37246479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
    Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
    BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Added Clinical Value of
    van Ginkel N; van Gennep EJ; Oosterbaan L; Greidanus J; Boellaard TN; Wondergem M; Vis AN; de Reijke TM; van Rhijn BWG; Mertens LS
    Clin Genitourin Cancer; 2023 Jun; 21(3):342-348. PubMed ID: 36918302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
    Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
    Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staging
    Voskuilen CS; van Gennep EJ; Einerhand SMH; Vegt E; Donswijk ML; Bruining A; van der Poel HG; Horenblas S; Hendricksen K; van Rhijn BWG; Mertens LS
    Eur Urol Oncol; 2022 Jun; 5(3):366-369. PubMed ID: 33583752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer.
    Chung YS; Kim HS; Lee JY; Kang WJ; Nam EJ; Kim S; Kim SW; Kim YT
    Cancer Res Treat; 2020 Oct; 52(4):1211-1218. PubMed ID: 32599990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
    J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer.
    Moussa M; Chakra MA; Saad W; Dellis A; Papatsoris A
    Urol Oncol; 2021 Dec; 39(12):833.e9-833.e17. PubMed ID: 34059435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of
    Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
    Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.